Tyme (TYME) 10-Q 11 Feb 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2018	Feb. 07, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q3
Trading Symbol	TYME
Entity Registrant Name	TYME TECHNOLOGIES, INC.
Entity Central Index Key	1,537,917
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		103,342,036

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 16,733,139	$ 28,975,822
Prepaid rent	242,755
Prepaid clinical costs	510,346
Prepaid expenses and other current assets	286,723	732,555
Total current assets	17,772,963	29,708,377
Property and equipment, net of accumulated depreciation	11,675	3,239
Prepaid clinical costs	1,266,025	1,306,225
Prepaid rent, net of current portion	161,836
Total assets	19,212,499	31,017,841
Current liabilities
Accounts payable and other current liabilities (including $181,000 and $384,000 of related party accounts payable, respectively)	2,295,250	2,817,090
Accrued bonuses	1,167,789	1,248,690
Insurance note payable	39,015	480,094
Total current liabilities	3,502,054	4,545,874
Total liabilities	3,502,054	4,545,874
Commitments and contingencies (see Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 103,190,385 and 101,226,479 issued and outstanding at December 31, 2018 and March 31, 2018, respectively	10,322	10,125
Additional paid in capital	90,317,576	79,293,423
Accumulated deficit	(74,617,453)	(52,831,581)
Total stockholders' equity	15,710,445	26,471,967
Total liabilities and stockholders' equity	$ 19,212,499	$ 31,017,841

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	103,190,385	101,226,479
Common stock, outstanding	103,190,385	101,226,479
Drinker, Biddle & Reath LLP ("DBR") [Member]
Related party accounts payable	$ 181,000	$ 384,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	4,525,228	2,585,991	10,979,432	6,402,270
General and administrative (including $132,000, $588,000, $794,000 and $1,559,000 of related party legal expenses, respectively)	3,550,223	2,975,274	10,827,879	7,644,476
Total operating expenses	8,075,451	5,561,265	21,807,311	14,046,746
Loss from operations	(8,075,451)	(5,561,265)	(21,807,311)	(14,046,746)
Other income	28,718		28,718	390,385
Interest expense	(1,221)		(7,279)
Net loss	$ (8,047,954)	$ (5,561,265)	$ (21,785,872)	$ (13,656,361)
Basic and diluted loss per common share	$ (0.08)	$ (0.06)	$ (0.21)	$ (0.15)
Basic and diluted weighted average shares outstanding	103,009,449	89,929,161	101,963,833	89,499,882

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Related party legal expenses	$ 132,000	$ 588,000	$ 794,000	$ 1,559,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - 9 months ended Dec. 31, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid-in capital [Member]	Accumulated Deficit [Member]
Balance, at beginning at Mar. 31, 2018	$ 26,471,967	$ 10,125	$ 79,293,423	$ (52,831,581)
Balance, at beginning (in shares) at Mar. 31, 2018	101,226,479	101,226,479
Issuance of common stock from at-the-market financing facility, net of associated expenses	$ 4,052,265	$ 179	4,052,086
Issuance of common stock from at-the-market financing facility, net of associated expenses (in shares)		1,779,872
Exercise of options	$ 270,000	$ 10	269,990
Exercise of options (in shares)	100,000	100,000
Cashless exercise of warrants		$ 8	(8)
Cashless exercise of warrants (in shares)		84,034
Stock based compensation	$ 6,702,085		6,702,085
Net loss	(21,785,872)			(21,785,872)
Balance, at end at Dec. 31, 2018	$ 15,710,445	$ 10,322	$ 90,317,576	$ (74,617,453)
Balance, at end (in shares) at Dec. 31, 2018	103,190,385	103,190,385

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2018
ATM Financing Facility [Member]
Offering expense	$ 125,327	$ 300,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (21,785,872)	$ (13,656,361)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	7,108	3,222
Amortization of employees, directors and consultants stock options	6,702,085	6,642,428
Gain on remeasurement of derivative liability		(390,385)
Change in operating assets and liabilities:
Prepaid rent	(404,591)
Prepaid expenses and other assets	445,832	(1,566,505)
Prepaid clinical costs	(470,146)
Accounts payable and other current liabilities	(521,841)	765,367
Accrued bonuses	(80,901)
Net cash used in operating expenses	(16,108,326)	(8,202,234)
Cash flows from investing activities
Purchase of property & equipment	(15,544)
Net cash used in investing activities	(15,544)
Cash flows from financing activities
Insurance note payments	(441,078)
Proceeds from private placement offering of common stock and warrants, net of issuance costs		2,597,100
Issuance of common stock from at-the-market financing	4,052,265	5,752,936
Proceeds from collection of stock subscription receivable		174,998
Proceeds from exercise of stock options	270,000
Net cash provided by financing activities	3,881,187	8,525,034
Net (decrease)increase in cash and cash equivalents	(12,242,683)	322,800
Cash and cash equivalents - beginning	28,975,822	10,482,977
Cash and cash equivalents - ending	16,733,139	10,805,777
Supplemental Cash Flow Information:
Interest	$ 7,279
Noncash investing and financing activities:
Derivative liability associated with the price protection feature of shares of common stock issued		$ 11,785

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Dec. 31, 2018shares
Statement Of Cash Flows [Abstract]
Cashless exercise of warrants	301,959
Cashless exercise of shares of common stock	84,034

Nature of Business

Nature of Business	9 Months Ended
	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Tyme Technologies, Inc. (“TYME”) is a Delaware corporation headquartered in New York, NY, with wholly-owned subsidiaries, Tyme Inc. and Luminant Biosciences, LLC (“Luminant”) (collectively, the “Company”). Prior to 2014, Luminant conducted the initial research and development of the Company’s therapeutic platform. Since January 1, 2014, the majority of the Company’s research, development and other business activities have been conducted by Tyme Inc., which was incorporated in Delaware in 2013. On October 27, 2016, the Board of Directors of TYME approved a change in fiscal year end from December 31 to March 31 of each year. The Company is a clinical stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across many tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company has ongoing IND-enabled Phase II clinical trials in metastatic pancreatic cancer and biomarker recurrent prostate cancer. In September 2018, the Company announced an investigator-initiated Phase II trial of SM-88 in patients with previously treated metastatic sarcoma. In addition, on October 9, 2018, the Company entered into a Clinical Research Funding and Drug Supply Agreement with the Pancreatic Cancer Action Network, Inc., a non-profit tax exempt organization (“PanCAN”), whereby SM-88 will be included as an experimental arm in the Precision Promise adaptive pivotal trial platform sponsored by PanCAN. The accompanying condensed consolidated financial statements include the results of operations of TYME and its wholly-owned subsidiaries. Liquidity The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. During fiscal year 2018, the Company raised gross proceeds of approximately $32.1 million through the issuance of its common stock, par value $0.0001 per share (“Common Stock”). Most recently in March 2018, the Company raised aggregate gross proceeds of $23.3 million before underwriting discounts and commissions and expenses of the offering through an underwritten public offering. Previously on November 2, 2017, the Company entered into an equity distribution agreement (“Equity Distribution Agreement”) with Canaccord Genuity Inc. (“Canaccord”), to commence an at-the-market offering (the “ATM Financing Facility”) pursuant to which the Company may, from time to time, subject to certain rules and regulations, sell shares of the Company’s Common Stock up to $30.0 million, through Canaccord, as the Company’s sales agent. In the year ended March 31, 2018, the Company raised approximately $6.2 million in aggregate gross proceeds before commissions and expenses through the ATM Financing Facility and paid Canaccord aggregate commissions of $0.3 million. For the nine months ended , 2018, the Company raised approximately $4.2 million in aggregate gross proceeds before commissions and expenses through the ATM Financing Facility and paid Canaccord aggregate commissions of $0.1 million. At , 2018, there remained approximately $19.6 million of availability to sell shares through the facility. On October 25, 2018, the Company decided to discontinue use of the ATM Financing Facility for the remainder of calendar year 2018, to be reassessed in calendar year 2019. The Company has concluded it intends to reopen the ATM Financing Facility for potential use shortly after the filing of this Form 10-Q (see Part 2. Item 5. Other Information). For the nine months ended December 31, 2018, the Company had negative cash flow from operations of $16.1 million and net loss of $21.8 million, which included $6.7 million Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in the aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements. The Company has developed an operational plan that manages expenses and delays initiation of certain operational initiatives to focus on core programs if appropriate funding is not available.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our condensed consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the year ended March 31, 2018 filed with the SEC on June 13, 2018 (the “2018 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of TYME and its subsidiaries, Tyme Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2018 included in the Company’s 2018 10-K. Reclassifications The Company has reclassified certain prior period amounts to conform to the current period presentation relating to prepaid clinical costs for $1,306,225. These reclassifications have no effect on the previously reported net loss or cash flows. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In July 2018, the FASB issued both ASU 2018-10, Codification Improvements to Topic 842, Leases (“ASU 2018-10”) and ASU 2018-11, Leases (Topic 842)—Targeted Improvements (“ASU 2018-11”), which provide additional guidance or clarifications affecting certain aspects of ASU 2016-02 and certain practical expedients. Further, the updated guidance allows an additional transition method to apply the new leases standard at the adoption date, as compared to the beginning of the earliest period presented, and to recognize a cumulative-effect adjustment to the beginning balance of retained earnings in the period of adoption . In June 2018, the FASB issued ASU 2018-07 which simplifies the accounting for share-based payments made to nonemployees so that the accounting for such payments is substantially the same as those made to employees, with certain exceptions. Under this ASU, equity-classified share based awards to nonemployees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees, unless the award is modified after the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing services. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective July 1, 2018.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Basic and diluted net loss per common share calculation: Net loss $ (8,047,954 ) $ (5,561,265 ) $ (21,785,872 ) $ (13,656,361 ) Weighted average common shares outstanding — basic and diluted: 103,009,449 89,929,161 101,963,833 89,499,882 Net loss per share of common stock — basic and diluted $ (0.08 ) $ (0.06 ) $ (0.21 ) $ (0.15 ) The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company common stock outstanding for the period, and diluted earnings per share is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive as the Company incurred losses for the periods then ended. The following outstanding securities at December 31, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: December 31 , 2018 2017 Stock options 8,931,305 5,240,120 Warrants 5,283,915 5,625,641 Total 14,215,220 10,865,761

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	9 Months Ended
	Dec. 31, 2018
Payables And Accruals [Abstract]
Accounts Payable and Other Current Liabilities	Note 4. Accounts Payable and Other Current Liabilities Accounts payable (including accounts payable to a related party – see Note 9) and other current liabilities consisted of the following: December 31, 2018 March 31, 2018 Legal 280,546 $ 421,128 Consulting 7,996 37,071 Accounting and auditing 181,258 81,652 Research and development 1,159,310 1,678,675 Board of Directors and Scientific Advisory 462,736 442,610 Other 203,404 155,954 Total $ 2,295,250 $ 2,817,090

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 5. Fair Value of Financial Instruments There are no assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 and March 31, 2018. The changes in the fair value of the derivative liability for the nine months ended December 31, 2017 are as follows: Fair value at March 31, 2017 $ 378,600 Fair value of liability-classified anti-dilution feature $ 11,785 Change in fair value of derivative liability (390,385 ) Fair value at December 31, 2017 $ — The fair value of the derivative liability was written down to zero as of September 30, 2017, as the anti-dilution provisions associated with a private placement in March 2017 expired

Debt

Debt	9 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt	Note 6. Debt Insurance Note Payable During the year ended March 31, 2018, the Company entered into a short-term financing arrangement with its insurance carrier related to payment of premium for its Director and Officer liability insurance coverage totaling $480,000 for the policy year ending on March 31, 2019. As of December 31, 2018 and March 31, 2018, there remained a balance of $39,000 and $480,000, respectively, recorded to Insurance note payable on the accompanying consolidated balance sheets.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	Note 7. Stockholders’ Equity Securities Purchase Agreements In April 2017, the Company raised $2.7 million in gross proceeds through a private placement (“April 2017 Private Placement”) of 1,069,603 shares of Common Stock and 1,069,603 common stock purchase warrants (each, a “Warrant”). Each Warrant entitles its holder to purchase one share of common stock (each, a “Warrant Share”) at an exercise price of $3.00 per Warrant Share. The Warrants expire two years from the date of issuance and vest immediately. The warrants are included within additional paid-in capital on the statement of stockholders’ equity and will not be subject to remeasurement. At December 31, 2018 and March 31, 2018, 5,254,148 and 5,556,107, respectively, of common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. The following summarizes the common stock warrant activity for the nine months ended December 31, 2018: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2018 5,585,874 $ 3.34 Less: Exercised (301,959 ) Outstanding at December 31, 2018 5,283,915 $ 3.35 At-the-Market Financing Facility On November 2, 2017, the Company entered into the Equity Distribution Agreement with Canaccord, to commence the ATM Financing Facility pursuant to which the Company may, from time to time, sell shares of the Company’s Common Stock having an aggregate offering price up to $30,000,000 through Canaccord, as the Company’s sales agent. For the nine months ended December 31, 2018, the Company sold 1,779,872 shares for net proceeds after commissions of $4,052,000. On October 25, 2018, the Company decided to discontinue use of the ATM Financing Facility for at least the remainder of calendar year 2018, to be reassessed in calendar year 2019. The Company has concluded it intends to reopen the use of the ATM Financing Facility shortly after the filing of this Form 10-Q (see Part 2. Item 5. Other Information). Public Offering In March 2018, the Company raised approximately $23,288,000 in gross proceeds through a public offering of 10,350,000 shares of its Common Stock. The Offering was made pursuant to the Company’s registration statement on Form S-3 (Registration No. 333-211489), which was declared effective by the U.S. Securities and Exchange Commission on August 16, 2017, a base prospectus dated August 16, 2017 and a prospectus supplement dated March 1, 2018. Share Registration On December 31, 2018, TYME filed a registration statement on Form S-3 (Registration No. 333-229104) with the Securities and Exchange Commission to register the resale of 12,093,745 shares of the Company’s common stock, including 5,254,148 issuable upon exercise of warrants, currently held by our security holders named therein. This registration statement referred to above is not yet effective. The securities were previously issued in connection with private financings completed during calendar years 2015, 2016 and 2017 as well as in private transactions with certain affiliates. Securities associated with these financings had not previously been registered. The Company is not selling any securities under this registration statement and will not receive any proceeds from the sale of our securities by the selling security holders, although we could receive certain proceeds upon the exercise of outstanding warrants referred to in the registration statement.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. Purchase Commitments During the fiscal year ended March 31, 2018, the Company entered into two contracts with manufacturers to supply certain components used in SM-88 in order to achieve favorable pricing on supplied products. These contracts have non-cancellable elements related to the scheduled deliveries of these products in future periods. Payments are made by us to the manufacturer when the products are delivered and of acceptable quality. The contracts are structured to match clinical supply needs for our ongoing trials and we expect the timing of the remaining associated payments to predominately occur during fiscal year 2020. During the three months ended September 30, 2018, the purchase commitment under one of the contracts was cancelled without penalty. During the three months ended December 31, 2018, the remaining contract was amended, increasing the contractual obligation by $338,000. Total outstanding future obligations associated with commitments were $1,074,486 at December 31, 2018, a decrease of $602,514 from $1,677,000 at March 31, 2018. In January 2019, the Company entered into an additional contract with a manufacturer for certain components used in SM-88 with an aggregated estimated cost to the Company of $550,000. Production and costs commenced in January 2019 and material is expected to be delivered in fiscal 2020. Lease In November 2018, the Company entered into a two-year lease for new office space in New Jersey with a monthly rent of $2,289 for the first six months and $4,292 for the remaining term. As per the lease agreement, the lease commencement is dependent on the performance of certain improvements by the landlord which were not completed as of December 31, 2018. As such, this lease is not accounted for in the accompanying financial statements as of December 31, 2018.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 9. Related Party Transactions Legal Drinker Biddle & Reath LLP (“DBR”) has provided legal services to the Company. A partner of DBR was a member of the Board of Directors and had received, and was entitled to receive in the future, cash compensation payable to non-employee directors and equity compensation payable to non-employee directors generally under the Amended and Restated 2016 Stock Option Plan for Non-Employee Directors. On September 10, 2018, the Company entered into an employment agreement with the partner and he was appointed as the Company’s Chief Legal Officer and Secretary. He ceased to be a non-employee director on September 10, 2018 and he resigned as a member of the Board, effective September 30, 2018. On September 1, 2018, the partner resigned from the partnership of DBR and he assumed the consulting role “of Counsel” with the firm. During the three and nine months ending December 31, 2018 and 2017, approximately $132,000, $794,000, $588,000, and $1,559,000, respectively, have been incurred as legal fees associated with DBR. At December 31, 2018 and March 31, 2018, the Company had approximately $181,000 and $384,000, respectively, in accounts payable and accrued expenses payable to DBR.

Equity Incentive Plan

Equity Incentive Plan	9 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	Note 10. Equity Incentive Plan Stock Options As of December 31, 2018, there was approximately $9,271,000 of total unrecognized compensation expense related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average service period of 1 On July 30, 2018, the Board approved modifications to the vesting terms of stock options awarded to employees and the Board of Directors under the 2015 Equity Incentive Plan on May 24, 2018 which previously vested over a four-year period (with 25% of the award vesting on the one-year anniversary of grant and the remaining vesting in pro rata quarterly increments), and were modified to vest instead on a three-year vesting schedule, vesting in pro rata quarterly increments. No other terms of these options were modified. Due to the accelerated vesting as a result of these modifications, the Company recorded an additional $432,000 of expense during the nine months ended December 31, 2018. Stock based compensation expense recognized was as follows: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 General and administrative $ 1,316,000 $ 1,400,000 $ 4,548,000 $ 3,300,000 Research and development 684,000 1,600,000 2,154,000 3,300,000 Total $ 2,000,000 $ 3,000,000 $ 6,702,000 $ 6,600,000 The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. For employees and non-employees, the compensation expense is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date. The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees in the current fiscal period has been based on the term by using the simplified method as allowed under SAB No. 110. The expected term of options granted to non-employees and consultants was based on the grant’s full contractual life. Effective July 1, 2018, the Company adopted ASU 2018-07 and, as such, the expected term is determined using the simplified method for options granted to non-employees and consultants. Prior to the three months ended December 31, 2017, the Company used the full contractual term as the expected term in its Black Scholes model to estimate stock option value. The Company used the full contractual term because there was no history of exercise activity and the stock was thinly-traded on the OTC Market. Beginning in the three months ended December 31, 2017, the Company determined the use of the simplified method was more appropriate than the full contractual term due to the increased trading volume and activity during the quarter and the increased market and demand for shares. Based on these factors, the Company deemed it no longer appropriate to use the full contractual term for expected life, because these changes in the business indicate the likelihood that there will be exercise activity before completion of the full contractual term. The Company considered other methods to estimate expected term other than the simplified method. However, as noted above, there is no historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded and no other refined estimate of expected life that is appropriate. The weighted average assumptions used to determine such values are presented in the following table: December 31, 2018 December 31, 2017 Risk free interest rate 2.90 % 2.13 % Expected volatility 74.89 % 83.41 % Expected term (in years) 5.8 years 7.6 years Dividend yield 0 % 0 % The following is a summary of the status of the Company’s stock options as of December 31, 2018: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2018 5,438,072 $ 5.11 Granted 3,643,233 2.65 Exercised (100,000 ) 2.70 Forfeited/Cancelled (50,000 ) 2.33 Outstanding at December 31, 2018 8,931,305 4.15 Options exercisable at December 31, 2018 4,893,714 4.90 Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at December 31, 2018 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at December 31, 2018 Weighted Average Exercise Price Aggregate Intrinsic Value $2.25-$8.75 8,931,305 $ 4.15 8.13 $ 5,563,315 4,893,714 $ 4.90 $ 1,644,654 The intrinsic value, which is calculated as the excess of the market value as of December 31, 2018 over the exercise price of the options, is approximately $5,563,000 and $1,645,000 for outstanding stock options and vested stock options, respectively. The market value per share as of December 31, 2018 was $3.69 as reported by the NASDAQ Capital Market.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. The Company weighed available positive and negative evidence and concluded that a full valuation allowance should continue to be maintained on its net deferred tax assets. The Company is required to evaluate uncertain tax positions taken or expected to be taken in the course of preparing the Company’s condensed consolidated financial statements to determine whether the tax positions are more likely than not of being sustained by the applicable tax authority. As of December 31, 2018, the Company’s uncertain tax positions remain unchanged. Due to the full valuation allowance, none of the gross unrecognized tax benefits would affect the effective tax rate at December 31, 2018, if recognized. The Company had no income tax related penalties or interest for periods presented in these condensed consolidated financial statements related to uncertain tax positions due to available net operating loss carryforwards, which would be recorded as tax expense should the Company accrue for such items. On December 22, 2017 the U.S. Tax Cuts and Jobs Act (“the Act”) was signed into legislation. The Act changed the Federal statutory tax rate to 21% for tax years beginning January 1, 2018. Because the Company has a full valuation allowance against its net deferred tax asset, the rate change has no effect on the Company’s income tax expense.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events In January 2019, 784,312 warrants were exercised on a cashless basis resulting in the issuance of 151,651 shares. On January 28, 2019, a purported stockholder filed a securities lawsuit against us and our CEO and CFO. The plaintiff purported to represent a class of stockholders for the period from March 14, 2018 through January 18, 2019, inclusive. Due to the recent status of the complaint, the Company is unable to estimate a potential loss or range of loss, if any, at this time (see Part II, Item 1. Legal Proceedings).

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our condensed consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the year ended March 31, 2018 filed with the SEC on June 13, 2018 (the “2018 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of TYME and its subsidiaries, Tyme Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2018 included in the Company’s 2018 10-K.
Reclassifications	Reclassifications The Company has reclassified certain prior period amounts to conform to the current period presentation relating to prepaid clinical costs for $1,306,225. These reclassifications have no effect on the previously reported net loss or cash flows.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In July 2018, the FASB issued both ASU 2018-10, Codification Improvements to Topic 842, Leases (“ASU 2018-10”) and ASU 2018-11, Leases (Topic 842)—Targeted Improvements (“ASU 2018-11”), which provide additional guidance or clarifications affecting certain aspects of ASU 2016-02 and certain practical expedients. Further, the updated guidance allows an additional transition method to apply the new leases standard at the adoption date, as compared to the beginning of the earliest period presented, and to recognize a cumulative-effect adjustment to the beginning balance of retained earnings in the period of adoption . In June 2018, the FASB issued ASU 2018-07 which simplifies the accounting for share-based payments made to nonemployees so that the accounting for such payments is substantially the same as those made to employees, with certain exceptions. Under this ASU, equity-classified share based awards to nonemployees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees, unless the award is modified after the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing services. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective July 1, 2018.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Basic and diluted net loss per common share calculation: Net loss $ (8,047,954 ) $ (5,561,265 ) $ (21,785,872 ) $ (13,656,361 ) Weighted average common shares outstanding — basic and diluted: 103,009,449 89,929,161 101,963,833 89,499,882 Net loss per share of common stock — basic and diluted $ (0.08 ) $ (0.06 ) $ (0.21 ) $ (0.15 )
Schedule of Anti-dilutive Shares Outstanding	The following outstanding securities at December 31, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: December 31 , 2018 2017 Stock options 8,931,305 5,240,120 Warrants 5,283,915 5,625,641 Total 14,215,220 10,865,761

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	9 Months Ended
	Dec. 31, 2018
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable (including accounts payable to a related party – see Note 9) and other current liabilities consisted of the following: December 31, 2018 March 31, 2018 Legal 280,546 $ 421,128 Consulting 7,996 37,071 Accounting and auditing 181,258 81,652 Research and development 1,159,310 1,678,675 Board of Directors and Scientific Advisory 462,736 442,610 Other 203,404 155,954 Total $ 2,295,250 $ 2,817,090

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Changes in Fair Value Derivative Liability	The changes in the fair value of the derivative liability for the nine months ended December 31, 2017 are as follows: Fair value at March 31, 2017 $ 378,600 Fair value of liability-classified anti-dilution feature $ 11,785 Change in fair value of derivative liability (390,385 ) Fair value at December 31, 2017 $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the nine months ended December 31, 2018: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2018 5,585,874 $ 3.34 Less: Exercised (301,959 ) Outstanding at December 31, 2018 5,283,915 $ 3.35

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	9 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock based compensation expense	Stock based compensation expense recognized was as follows: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 General and administrative $ 1,316,000 $ 1,400,000 $ 4,548,000 $ 3,300,000 Research and development 684,000 1,600,000 2,154,000 3,300,000 Total $ 2,000,000 $ 3,000,000 $ 6,702,000 $ 6,600,000
Schedule of Assumptions Used to Estimate the Fair Value of Stock Options Granted	The weighted average assumptions used to determine such values are presented in the following table: December 31, 2018 December 31, 2017 Risk free interest rate 2.90 % 2.13 % Expected volatility 74.89 % 83.41 % Expected term (in years) 5.8 years 7.6 years Dividend yield 0 % 0 %
Schedule of Stock Options	The following is a summary of the status of the Company’s stock options as of December 31, 2018: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2018 5,438,072 $ 5.11 Granted 3,643,233 2.65 Exercised (100,000 ) 2.70 Forfeited/Cancelled (50,000 ) 2.33 Outstanding at December 31, 2018 8,931,305 4.15 Options exercisable at December 31, 2018 4,893,714 4.90
Schedule of Stock Option by Exercise Price Range	Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at December 31, 2018 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at December 31, 2018 Weighted Average Exercise Price Aggregate Intrinsic Value $2.25-$8.75 8,931,305 $ 4.15 8.13 $ 5,563,315 4,893,714 $ 4.90 $ 1,644,654

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018	Nov. 02, 2017
Nature of Business [Line Items]
Cash proceeds from private placement			$ 4,052,265	$ 5,752,936	$ 32,100,000
Common stock, par value	$ 0.0001		$ 0.0001		$ 0.0001
Aggregate offering						$ 30,000,000
Available for offering	$ 19,600,000		$ 19,600,000
Net cash used in operating activities	(5,200,000)		(16,108,326)	(8,202,234)
Net loss	(8,047,954)	$ (5,561,265)	(21,785,872)	$ (13,656,361)
Non-cash expense	2,000,000		6,700,000
Working capital	$ 14,300,000		14,300,000
Underwriters Public Offering [Member]
Nature of Business [Line Items]
Cash proceeds from private placement					$ 23,300,000
ATM Financing Facility [Member]
Nature of Business [Line Items]
Cash proceeds from private placement			4,200,000		6,200,000
Offering expense			$ 125,327		$ 300,000

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Accounting Policies [Abstract]
Prepaid clinical costs	$ 1,266,025	$ 1,306,225

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Basic and diluted net loss per common share calculation:
Net loss	$ (8,047,954)	$ (5,561,265)	$ (21,785,872)	$ (13,656,361)
Weighted average common shares outstanding — basic and diluted	103,009,449	89,929,161	101,963,833	89,499,882
Net loss per share of common stock — basic and diluted	$ (0.08)	$ (0.06)	$ (0.21)	$ (0.15)

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Detail) - shares	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	14,215,220	10,865,761
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	8,931,305	5,240,120
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	5,283,915	5,625,641

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Detail) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Payables And Accruals [Abstract]
Legal	$ 280,546	$ 421,128
Consulting	7,996	37,071
Accounting and auditing	181,258	81,652
Research and development	1,159,310	1,678,675
Board of Directors and Scientific Advisory	462,736	442,610
Other	203,404	155,954
Total	$ 2,295,250	$ 2,817,090

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Additional Information (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)	Dec. 31, 2018	Mar. 31, 2018	Sep. 30, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 0	$ 0
Liabilities measured at fair value	$ 0	$ 0
Derivative liability - anti-dilution feature			$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Changes in Fair Value Derivative Liability (Detail)	9 Months Ended
	Dec. 31, 2017USD ($)
Derivative Liabilities [Abstract]
Fair value at March 31, 2017	$ 378,600
Fair value of liability-classified anti-dilution feature	11,785
Change in fair value of derivative liability	$ (390,385)

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	9 Months Ended
	Dec. 31, 2018	Mar. 31, 2018
License Agreement [Line Items]
Remaining insurance note payable	$ 39,015	$ 480,094
Insurance Note Payable [Member]
License Agreement [Line Items]
Principal amount		480,000
Remaining insurance note payable	$ 39,000	$ 480,000
Maturity period	March 31, 2019

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended		12 Months Ended
	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018	Nov. 02, 2017
Class Of Warrant Or Right [Line Items]
Aggregate offering					$ 30,000,000
Available for offering		$ 19,600,000
Gross proceeds through public offering		$ 4,052,265	$ 5,752,936	$ 32,100,000
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Exercise price		$ 3.35		$ 3.34
Common stock purchase warrants outstanding and exercisable		5,283,915		5,585,874
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue		1,779,872
April 2017 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Total gross proceeds from private placement	$ 2,700,000
Number of shares issued upon new issue	1,069,603
April 2017 Private Placement [Member] | Warrant [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue	1,069,603
Warrant to purchase common stock shares	1
Exercise price	$ 3
Vesting period	2 years
Private Placement [Member] | Warrant [Member] | Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Common stock purchase warrants outstanding and exercisable		5,254,148		5,556,107
ATM Financing Facility [Member]
Class Of Warrant Or Right [Line Items]
Net proceeds after commissions from issuance of common stock		$ 4,052,000
Gross proceeds through public offering		$ 4,200,000		$ 6,200,000
ATM Financing Facility [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue		1,779,872
Public Offering [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue				10,350,000
Gross proceeds through public offering				$ 23,288,000
Share Re-sale [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue		0
Common stock, shares resale		12,093,745
Shares issuable upon exercise of warrants		5,254,148
Proceeds from the sale of securities		$ 0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail) - Warrant [Member]	9 Months Ended
	Dec. 31, 2018$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrant Shares of Common Stock, Outstanding at beginning	5,585,874
Warrant Shares of Common Stock, Less: Exercised	(301,959)
Warrant Shares of Common Stock, Outstanding at ending	5,283,915
Weighted Average Exercise Price, Outstanding at beginning | $ / shares	$ 3.34
Weighted Average Exercise Price, Outstanding at ending | $ / shares	$ 3.35

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Jan. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018Contract	Sep. 30, 2018USD ($)	Mar. 31, 2018USD ($)Contract	Nov. 30, 2018
Commitment And Contingencies [Line Items]
Number of contracts | Contract					2
Number of contracts cancelled | Contract			1
Increase in contractual obligation		$ 338,000
Contractual obligation		1,074,486
Lease term contract						2 years
Monthly rent		$ 4,292		$ 2,289
Subsequent Event [Member]
Commitment And Contingencies [Line Items]
Aggregated estimated contract cost	$ 550,000
Maximum [Member]
Commitment And Contingencies [Line Items]
Contractual obligation					$ 1,677,000
Minimum [Member]
Commitment And Contingencies [Line Items]
Contractual obligation					$ 602,514

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Drinker, Biddle & Reath LLP ("DBR") [Member] - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018
Related Party Transaction [Line Items]
Legal expenses	$ 132,000	$ 588,000	$ 794,000	$ 1,559,000
Accounts payable and accrued expenses payable	$ 181,000		$ 181,000		$ 384,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail) - USD ($)	Jul. 30, 2018	May 24, 2018	Dec. 31, 2018
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Unrecognized compensation expense			$ 9,271,000
Unrecognized compensation expense recognition period			1 year
Number of shares available for grants			4,657,122
Equity Incentive Plan 2015 [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Vesting terms			On July 30, 2018, the Board approved modifications to the vesting terms of stock options awarded to employees and the Board of Directors under the 2015 Equity Incentive Plan on May 24, 2018 which previously vested over a four-year period (with 25% of the award vesting on the one-year anniversary of grant and the remaining vesting in pro rata quarterly increments), and were modified to vest instead on a three-year vesting schedule, vesting in pro rata quarterly increments.
Vesting period	3 years	4 years
Accelerated vesting, additional expense			$ 432,000
Equity Incentive Plan 2015 [Member] | One-Year Anniversary [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Vesting, percentage	25.00%
Equity Incentive Plan 2015 and 2016 [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Aggregate Intrinsic Value, options outstanding			5,563,000
Aggregate Intrinsic Value, options vested and expected to vest			$ 1,645,000
Share price (in dollars per share)			$ 3.69

Equity Incentive Plan - Allocat

Equity Incentive Plan - Allocation of Share Based Compensation (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 2,000,000	$ 3,000,000	$ 6,702,000	$ 6,600,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	1,316,000	1,400,000	4,548,000	3,300,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 684,000	$ 1,600,000	$ 2,154,000	$ 3,300,000

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Used to Estimate the Fair Value of Stock Options Granted (Detail)	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]
Risk free interest rate	2.90%	2.13%
Expected volatility	74.89%	83.41%
Expected term (in years)	5 years 9 months 18 days	7 years 7 months 6 days
Dividend yield	0.00%	0.00%

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Detail)	9 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	5,438,072
Granted | shares	3,643,233
Exercised | shares	(100,000)
Forfeited/Cancelled | shares	(50,000)
Outstanding at ending | shares	8,931,305
Options exercisable | shares	4,893,714
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 5.11
Granted | $ / shares	2.65
Exercised | $ / shares	2.70
Forfeited/Cancelled | $ / shares	2.33
Outstanding at ending | $ / shares	4.15
Options exercisable | $ / shares	$ 4.90

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Detail) - Exercise Price $2.25 - $8.75 [Member]	9 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Stock Options Outstanding
Range of Exercise Price, Lower Limit	$ 2.25
Range of Exercise Price, Upper Limit	$ 8.75
Number Outstanding | shares	8,931,305
Weighted Average Exercise Price	$ 4.15
Weighted Average Remaining Life (Years)	8 years 1 month 17 days
Aggregate Intrinsic Value | $	$ 5,563,315
Stock Options Vested
Stock Options Vested | shares	4,893,714
Weighted Average Exercise Price	$ 4.90
Aggregate Intrinsic Value | $	$ 1,644,654

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	9 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Corporate tax rate	21.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member]	1 Months Ended
	Jan. 31, 2019shares
Subsequent Event [Line Items]
Warrants exercised	784,312
Warrants issuance of shares	151,651